Rheumatoid Arthritis

      RA pts have ↑ risk of DVT (HR 2.26) & PE (HR 1.61) vs controls in this 40-year, pop-based study. Nodules, obesity,

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      RA pts have ↑ risk of DVT (HR 2.26) & PE (HR 1.61) vs controls in this 40-year, pop-based study. Nodules, obesity, high disease activity & early biologic use ↑ risk. Remission in year 1 halved PE risk. VTE risk persists despite therapeutic advances. @RheumNow #EULAR2025 #OP0070 https://t.co/AaBi2o2cUw
      A PT-led vocational intervention for RA/axSpA with reduced work ability was likely cost-effective: ↓€4,324 in societ

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      A PT-led vocational intervention for RA/axSpA with reduced work ability was likely cost-effective: ↓€4,324 in societal costs & +0.05 QALYs over 12m vs usual care (95% probability at €20k/QALY). Results suggest cost-effective compared to usual care. @RheumNow #EULAR2025 #OP0007
      RA polygenic risk ≠ MI risk. In >8,700 Swedes w/ or w/o RA, higher genetic risk for RA wasn’t linked to higher MI

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      RA polygenic risk ≠ MI risk. In >8,700 Swedes w/ or w/o RA, higher genetic risk for RA wasn’t linked to higher MI incidence. Familial clustering of RA & MI likely driven by non-genetic factors. Traditional CV risk still key in RA care. @RheumNow #EULAR2025 #OP0072 https://t.co/KN6Dg0ekt2
      If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix?

      Leiden po

      David Liew drdavidliew

      4 months 2 weeks ago
      If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden post-hoc trial: these patients don’t do worse than those who never get off drug. Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/QDxNRPN9f1
      First line TNFi in RA in 140+ pts vs Standard of Care
      At 5 yrs outcome
      OR drug free remission 2.2
      But no longer signific

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      First line TNFi in RA in 140+ pts vs Standard of Care At 5 yrs outcome OR drug free remission 2.2 But no longer significant at 10yrs OR sustained remission 10yrs 1.91 OR single bioDMARDs 10yrs 2.64 Less 1% D2T #Poster0027 #EULAR2025 @RheumNow https://t.co/sL2XCbxPbl
      Comparative efficacy of tofacitinib vs. adalimumab in RA - metanalysis of 9 RCTs, 24,643 pts finds Tofa signif superior

      Dr. John Cush RheumNow

      4 months 2 weeks ago
      Comparative efficacy of tofacitinib vs. adalimumab in RA - metanalysis of 9 RCTs, 24,643 pts finds Tofa signif superior to ADA for ACR20 (RR 1.28), HAQ-DI, VAS, but no difference in adverse events (RR 0.96) or DAS28-CRP improvement https://t.co/5mVY2Qvdms https://t.co/czxnlYHEAl
      Ph 2 open label RCT TOFA in RA-ILD 52 wks
      39pts 92% AE 8% 3 deaths FVC decline -69 ml
      No diff between UIP, NSIP or antif

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      Ph 2 open label RCT TOFA in RA-ILD 52 wks 39pts 92% AE 8% 3 deaths FVC decline -69 ml No diff between UIP, NSIP or antifibrotic No control group #POS0619 #EULAR2025 @RheumNow https://t.co/3lqEUfObG9
      Early PsA? Treat fast, treat hard.

      The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 res

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Early PsA? Treat fast, treat hard. The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations. Abstract#OP0092 @RheumNow #EULAR2025 https://t.co/cAZTc9eN16
      #OP0066 Danish registry study finds no increased risk of cancer recurrence with bDMARDs vs csDMARDs in RA patients with

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      #OP0066 Danish registry study finds no increased risk of cancer recurrence with bDMARDs vs csDMARDs in RA patients with prior solid tumor in remission. IPTW-adjusted HR for any bDMARD: 0.92 (95% CI 0.38–2.21). 📉 TNFi, ,RTX also not associated with recurrence @RheumNow #EULAR2025
      In #InflammatoryArthritis, baseline depression was linked to ↑ presenteeism & ↓ QoL at baseline + 3mo, but not a

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      In #InflammatoryArthritis, baseline depression was linked to ↑ presenteeism & ↓ QoL at baseline + 3mo, but not absenteeism. Data from 9-country study provide further evidence that mental health is key to supporting work outcomes in RA, PsA & axSpA. @RheumNow #EULAR2025 #OP0028
      Worried about cancer risk with ts/bDMARDs in RA?

      Real-world data from over 4,600 patients says: don’t be. No increase

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Worried about cancer risk with ts/bDMARDs in RA? Real-world data from over 4,600 patients says: don’t be. No increased risk of cancer (incl. NMSC) for JAKi, IL6i, CD20i, or CTLA4-A vs TNFi in long-term registry follow-up. Abstract#OP0065 @RheumNow #EULAR2025
      STAMP RCT early SEC vs. SoC 120pts
      Retention 58% vs 30%
      ACR 20, 50, 70 and MDA: better outcome at Month 3 but no differe

      Aurelie Najm AurelieRheumo

      4 months 2 weeks ago
      STAMP RCT early SEC vs. SoC 120pts Retention 58% vs 30% ACR 20, 50, 70 and MDA: better outcome at Month 3 but no difference at Month 6 Dactylitis no difference Of note here SoC was a tight T2T strategy! @RheumNow #OP0092 #EULAR2025 https://t.co/8zHs5CRFV5
      What happens in pre-RA when you stop #abatacept after 1 yr Rx

      At 6 yrs approx 60% on #Placebo
      V
      50% who initially got

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      What happens in pre-RA when you stop #abatacept after 1 yr Rx At 6 yrs approx 60% on #Placebo V 50% who initially got #ABA Prolonged damped effect of development of #RA NNT for 1 yr is ~10 with a range as low as 6 #EULAR2025 @RheumNow @eular_org Abst#OP0004 https://t.co/1VOEaZ00Ia
      older woman with clasped hands
      Late-Onset Disease: Different Age, Different Rules?
      4 months 2 weeks ago
      We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related biology, comorbidity, and the biases that influence medical decision-making? Several abstracts presented at EULAR 2025 challenge us to reconsider how we diagnose and treat rheumatic disease in older adults.
      Risk of #VTE in #rheumatoid #arthritis
      Is it better over last 25 yrs?

      👎

      Olmstead
      County population study of #RA Pt

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      Risk of #VTE in #rheumatoid #arthritis Is it better over last 25 yrs? 👎 Olmstead County population study of #RA Pts vs matched controls ⬆️VTE in RA ⬆️VTE w active RA But not change in rates of #DVT & #PE since 2000 Why? 🤔 Abst#OP0070 @rheumnow #EULAR2025 @eular_org https://t.co/eSyjfjVqtY

      Catch up on Conference Podcasts

      ×